Why Is VIR BIOTECHNOLOGY IN (VIR) Stock Up Today?

Vir Biotechnology shares rose 12.00% to $13.68 on Monday. The primary driver was the announcement of positive topline results from the Phase 3 ECLIPSE 1 trial for its hepatitis delta therapy. The combination of elebsiran and tobevibart met both primary and secondary endpoints.

What Happened

Vir Biotechnology reported that its Phase 3 ECLIPSE 1 trial for chronic hepatitis delta successfully met the primary endpoint. The data showed that 44% of patients achieved undetectable virus levels plus ALT normalization, compared to 0% in the delayed treatment group. The company also disclosed expanded data from the Phase 2 SOLSTICE trial, noting that all 28 patients completing 96 weeks had undetectable virus. A Form 8-K was filed with the SEC on November 9, 2026, disclosing these Regulation FD materials and financial statements. The stock had previously hit fresh 52-week highs on Friday, November 9, as markets awaited this data.

What The Data Shows

The stock opened at $14.64, a 19.9% gap from the prior close of $12.21. It reached a session high of $15.09 at 7:10 AM ET before pulling back to a session low of $12.64 at 9:20 AM ET. Volume so far stands at 0.9 million shares, which is 0.5 times the 3-month daily average. The company has a market capitalization of $2.1 billion and remains unprofitable with a trailing twelve-month EPS of -1.18. Revenue grew 1696.0% over the same period, though the net margin is -61.0%. The stock has a beta of 1.74 and a 52-week range of $4.82 to $12.45. Over the last eight sessions, the stock moved up 2.3% from $11.93 to $12.21. Recent insider activity includes one sale totaling $42,000 by EVP and General Counsel Vanina De Verneuil on November 2, 2026.

What To Watch

Investors will monitor the company’s upcoming earnings date and how the market digests the full Phase 3 data. The stock’s recent momentum and high beta suggest continued volatility as analysts update their models following the trial success.